NCT00363831Unknown2 期
A Multi-center Phase II Trial of Capecitabine in Combination With Oxaliplatin (Xelox) as First Line Chemotherapy in Patients With Metastatic Nasopharyngeal Carcinoma (NPC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Overall response rate (based on RECIST criteria)
研究概览
简要总结
Primary:
- To evaluate the efficacy of capecitabine in combination with oxaliplatin (XELOX) in terms of overall response rate (based on RECIST criteria) in patients with metastatic NPC without prior chemotherapy for relapse.
Secondary:
- To evaluate the efficacy profile of oxaliplatin (XELOX) in patients with metastatic NPC in terms of time to progression of disease, survival time, duration of response and complete response rate.
- To study the safety and tolerability of the regimen in patients with metastatic NPC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed poorly differentiated or undifferentiated nasopharyngeal carcinoma (WHO type II and III) with distant metastasis (ie. other than loco-regional disease). Patients with stage IVc disease, ie. distant metastases on presentation are also eligible.
- •Have at least one measurable lesion according to RECIST which has not been irradiated.
- •WBC count ≥ 3 x 10^9 /L with neutrophils ≥ 1.5 x 10^9 /L, platelet count ≥ 100 x 10^9 /L and Hb ≥ 9g/dL.
- •Serum creatinine ≤ 1.25 ULN
- •Be ambulatory and have a Karnofsky Performance Status of ≥ 70% at study entry.
- •Recover from prior radiotherapy prior to study entry
- •Effective contraception for both male and female if the risk of conception exists.
- •Able to swallow and retain oral medication.
排除标准
- •Previous cytotoxic chemotherapy for recurrent or metastatic NPC.
- •Previous exposure to oxaliplatin and/or capecitabine.
- •Pregnant or lactating women. Women of childbearing potential with either positive or no pregnancy test at baseline. Women of childbearing potential not using a reliable and appropriate contraceptive method. (Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential)
- •Sexually active males unwilling to practice contraception during the study.
- •Clinically significant cardiac disease (eg. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months.
- •Patients with a history of central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake.
- •History of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix.
- •Abnormal blood counts, AST, ALT, bilirubin and/or serum creatinine beyond the limits specified in the inclusion criteria.
- •Radiotherapy within 4 weeks of treatment start or prior radiotherapy to the indicator lesion(s) being measured in the study (newly arising marker lesions in previously irradiated areas are acceptable).
- •Major surgery within 4 weeks of the start of study treatment, without complete recovery.
- •Participation in any investigational drug study within 4 weeks preceding the start of treatment.
- •Symptomatic peripheral neuropathy NCI-CTCAE grade ≥
- •Known allergic/hypersensitivity reaction to any of the components of study treatments.
- •Serious uncontrolled intercurrent infections.
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究组 & 干预措施
1
Experimental
Oxaliplatin
干预措施: Oxaliplatin (Drug)
结局指标
主要结局
Overall response rate (based on RECIST criteria)
时间窗: From the beginning to the end of the study
次要结局
- Time to progression(From the beginning to the end of the study)
- Overall survival time(From the beginning to the end of the study)
- Adverse events(From the beginning to the end of the study)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal CancerColorectal CancerNCT00220116Royal Marsden NHS Foundation Trust172
终止
2 期
A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular CancerHepatocellular CancerLiver CancerNCT03026803City of Hope Medical Center4
Unknown
2 期
Efficacy and Safety of Oxaliplatin Combined With Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer PatientsColorectal CancerNCT02415829Fudan University55
已完成
不适用
A Phase II Study of Capecitabine, Oxaliplatin (XELOX) and Bevacizumab for patient with high-risk Upper Rectal Cancer as Neo-Adjuvant chemotherapy.pper rectal cancerJPRN-UMIN000015765Cancer Institute Hospital of Japanese Foundation for Cancer Research19
终止
2 期
Title XELOX FOR SALIVARY GLAND CANCERSHead and Neck CancerNCT00101075Dana-Farber Cancer Institute9